Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Irritable Bowel Syndrome (IBS) Treatment Market

Irritable Bowel Syndrome (IBS) Treatment Market Share

Report ID: GMI10525
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Irritable Bowel Syndrome Treatment Market Share

The irritable bowel syndrome treatment industry is characterized by the presence of several established and emerging players that offer a variety of products across the globe. The market players compete based on factors such as product quality, innovation, regulatory compliance, customer service, and pricing strategies.

Irritable Bowel Syndrome Treatment Market Companies

Prominent players operating in the irritable bowel syndrome treatment industry include:

Ardelyx
Astellas Pharma, Inc.
Bausch Health
Bayer
Ironwood Pharmaceuticals, Inc.
Johnson & Johnson
Sanofi
Sebela Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Validus Pharmaceuticals LLC

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The IBS treatment industry was valued at USD 3.3 billion in 2023 and is anticipated to witness 8.6% CAGR over 2024-2032, driven by the increasing prevalence of IBS.

The antidiarrheals segment of the irritable bowel syndrome treatment industry is anticipated to grow at 8.5% CAGR through 2032, as EHR systems play a pivotal role in centralizing patient data management.

North America irritable bowel syndrome treatment market size was valued at USD 1.3 billion in 2023 and is predicted to grow at 8.1% CAGR through 2032, driven by the region's advanced healthcare infrastructure.

Johnson & Johnson, Sanofi, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Validus Pharmaceuticals LLC among others.